{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008063","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.652167+00:00","generated_at":"2026-06-02T01:12:34.496118+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xilio Q1 net loss $17.2M; Gilead deal funds cash runway into Q2 2025","bullets":["Net loss $17.2M in Q1 2024 vs $22.6M YoY; cash and equivalents $34.0M at March 31.","In April 2024 received $30M upfront + $13.5M equity from Gilead; up to $592.5M in potential milestones.","Plan to initiate Phase 2 trial for XTX101 (anti-CTLA-4) in MSS CRC in Q3 2024; data in Q4 2024.","Discontinued XTX202 monotherapy; exploring combo development opportunities.","Cash runway expected into Q2 2025, including $44.6M in April gross proceeds from Gilead and private placements."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008063","json":"https://secwatch.observer/filing/0001558370-24-008063.json","markdown":"https://secwatch.observer/filing/0001558370-24-008063.md","text":"https://secwatch.observer/filing/0001558370-24-008063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024008063/0001558370-24-008063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024008063/xlo-20240514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:12:34.496118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c3d4d2240406e7366ddeebff5cab50a71cf3fc0c","claim":"Xilio Therapeutics, Inc. reported financial results for quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024008063/0001558370-24-008063-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}